期刊文献+

miR-873抑制肝细胞癌的侵袭与迁移 被引量:3

miR-873 supresses invasion and metastasis of hepatocellular carcinoma
下载PDF
导出
摘要 目的:检测miR-873在肝细胞癌(hepatocellular carcinoma,HCC)中的表达情况,探究其与HCC临床病理特征及HCC病人预后的相关性,进一步探究其对HCC细胞侵袭与迁移的影响。方法:应用Real-time PCR法检测90例HCC组织和对应癌旁组织中miR-873的表达水平;应用统计学方法分析miR-873的表达水平与HCC临床病理特征的相关性及对HCC病人预后的影响;应用Real-time PCR法检测HCC细胞系中miR-873的表达水平,并应用Transwell小室实验探究miR-873对HCC细胞侵袭与迁移能力的影响。结果:miR-873在90例HCC组织中的表达水平较癌旁组织显著下调(P<0.05);miR-873的表达水平与肿瘤数目、静脉侵犯、Edmondson病理分级及TNM分期显著相关(P<0.05);Kaplan-Meier曲线分析发现,miR-873低表达的患者生存率较差(P<0.05),且miR-873可作为肝癌病人术后生存的独立预测指标;miR-873在HCC细胞系中(Hep3B、MHCC-97H、HepG2、SMMC-7721)的表达较正常肝细胞LO2显著下调(P<0.05);Transwell小室实验显示miR-873能显著抑制HCC细胞的侵袭与迁移能力。结论:miR-873在HCC中表达下调,与HCC的临床病理及HCC病人的预后相关,并且能够抑制HCC细胞的侵袭与迁移能力。 Objective:To detect the expression level of miR-873 in hepatocellular carcinoma,and explore the clinical significance and functions of miR-873 in invasion and metastasis of hepatocellular carcinoma.Methods:Real-time PCR was performed to investigate the miR-873 expression in 90 paired HCC tissues and adjacent normal tissues.The clinical significance of miR-873 and its effects on HCC patients prognosis were analysed by statistics analysis.Real-time PCR was performed to detect the miR-873 expression in HCC cell lines.Transwell assay was applied to explore the functions of miR-873 in metastasis and invasion of HCC.Results:The expression level of miR-873 in both HCC tissues and cell lines was significantly down-regulared(P〈0.05),and miR-873 expression level was associated with tumor number,vein invasion,Edmondson-Steiner grading and tumor-node-metastasis (TNM) stage.Kaplan-Meier survival curves revealed that patients with lower miR-873 expression had a significantly reduced survival rate than those with high miR-873 expression (P〈0.05),and miR-873 could be an independent prognostic factor for HCC patients.Results of Transwell assay suggested that miR-873 could supress invasion and metastasis of HCC cells.Conclusion:miR-873 was down-regulated in HCC,and was associated with tumor number,vein invasion,Edmondson-Steiner grading and TNM stage and prognosis of HCC patients.miR-873 could supress invasion and metastasis of HCC cells.
出处 《现代肿瘤医学》 CAS 2017年第22期3648-3652,共5页 Journal of Modern Oncology
关键词 miR-873 肝细胞癌 侵袭 迁移 miR - 873, hepatocellular carcinoma, invasion, metastasis
  • 相关文献

参考文献1

二级参考文献66

  • 1Rossella Elisei,Martin J. Schlumberger,Stefan P. Müller,Patrick Sch?ffski,Marcia S. Brose,Manisha H. Shah,Lisa Licitra,Barbara Jarzab,Viktor Medvedev,Michael C. Kreissl,Bruno Niederle,Ezra E.W. Cohen,Lori J. Wirth,Haythem Ali,Colin Hessel,Yifah Yaron,Douglas Ball,Barry Nelkin,Steven I. Sherman.Cabozantinib in Progressive Medullary Thyroid Cancer[J]. Journal of Clinical Oncology . 2013 (29)
  • 2Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 3Shukui Qin,Yuxian Bai,Ho Yeong Lim,Sumitra Thongprasert,Yee Chao,Jia Fan,Tsai-Shen Yang,Vajarabhongsa Bhudhisawasdi,Won Ki Kang,Yu Zhou,Jee Hyun Lee,Yan Sun.Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J].Journal of Clinical Oncology.2013(28)
  • 4Ahmad A Tarhini.Tremelimumab: a review of development to date in solid tumors[J]. Immunotherapy . 2013 (3)
  • 5Rebecca L. Siegel,Kimberly D. Miller,Ahmedin Jemal.Cancer statistics, 2015[J]. CA: A Cancer Journal for Clinicians . 2015 (1)
  • 6Mairéad G. McNamara,Lisa W. Le,Anne M. Horgan,Alex Aspinall,Kelly W. Burak,Neesha Dhani,Eric Chen,Mehrdad Sinaei,Glen Lo,Tae Kyoung Kim,Patrik Rogalla,Oliver F. Bathe,Jennifer J. Knox.A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma[J]. Cancer . 2015 (10)
  • 7Hanning You,Wei Ding,Hien Dang,Yixing Jiang,C. Bart Rountree.??c‐Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma<link href='#fn2'/><link href='#fn1'/>(J)Hepatology . 2011 (3)
  • 8Hodi FS,O’’Day SJ,Mc Dermott DF,Weber RW,Sosman JA,Haanen JB,Gonzalez R,Robert C,Schadendorf D,Hassel JC,Akerley W,van den Eertwegh AJ,Lutzky J,Lorigan P,Vaubel JM,Linette GP,Hogg D,Ottensmeier CH,LebbéC,Peschel C,Quirt I,Clark JI,Wolchok JD,Weber JS,Tia.Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine . 2010
  • 9Bruno Sangro,Carlos Gomez-Martin,Manuel de la Mata,Mercedes I?arrairaegui,Elena Garralda,Pilar Barrera,Jose Ignacio Riezu-Boj,Esther Larrea,Carlos Alfaro,Pablo Sarobe,Juan José Lasarte,Jose L. Pérez-Gracia,Ignacio Melero,Jesús Prieto.??A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C(J)Journal of Hepatology . 2013 (1)
  • 10Zhu AX,Kudo M,Assenat E,Cattan S,Kang YK,Lim HY,Poon RT,Blanc JF,Vogel A,Chen CL,Dorval E,Peck-Radosavljevic M,Santoro A,Daniele B,Furuse J,Jappe A,Perraud K,Anak O,Sellami DB,Chen LT.Effect of evero-limus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial. The Journal of The American Medical Association . 2014

共引文献13

同被引文献23

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部